M.R. García Campelo

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Enriqueta Felip, Byoung Chul Cho, Adlinda Alip et al. · Annals of Oncology · 2024 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Benjamin Besse, Enriqueta Felip, Rosario García Campelo et al. · Annals of Oncology · 2023 · 70 citations · Full text

Medicine, Immunology, Oncology +17

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

Ma Carmen Areses Manrique, Joaquín Mosquera, Jorge García et al. · Translational Lung Cancer Research · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations

C. Zhou, Suresh S. Ramalingam, B. Li et al. · Journal of Thoracic Oncology · 2021 · 28 citations · Full text

Medicine, Oncology, Pharmacology +15

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial

M-J. Ahn, S-W. Kim, Laura Rodríguez et al. · Annals of Oncology · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacology +15